Petr Hosek
Overview
Explore the profile of Petr Hosek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
738
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fiala O, Hosek P, Korunkova H, Tkadlecova M, Hora M, Sikova D, et al.
In Vivo
. 2025 Feb;
39(2):859-869.
PMID: 40010964
Background/aim: New generation androgen receptor-targeting agents (ARTA) have been in the spotlight for their efficacy in metastatic castration-resistant prostate cancer (mCRPC). Prostate-specific antigen (PSA) represents one of the most commonly...
2.
Maceckova D, Vankova L, Bufka J, Hosek P, Moravec J, Pitule P
Mol Biol Rep
. 2024 Dec;
52(1):57.
PMID: 39692897
Background: The genetic and epigenetic alterations observed in acute myeloid leukemia (AML) contribute to its heterogeneity, influencing disease progression response to therapy, and patient outcomes. The use of antisense oligonucleotides...
3.
Trailin A, Ali E, Ye W, Pavlov S, cervenkova L, Vycital O, et al.
Int J Cancer
. 2024 Nov;
156(6):1282-1292.
PMID: 39508720
Prognostic value of T-cells between primary colorectal cancer (pCRC) and its paired synchronous and metachronous liver metastasis (LM) is underinvestigated and is the subject of the present study. We enrolled...
4.
Svaton M, Havel D, Buresova M, Baxa J, Hosek P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
. 2024 Oct;
169(1):21-25.
PMID: 39351663
Aim: Percutaneous transthoracic needle biopsy (PTNB), an alternative to bronchoscopic confirmation of lung lesions, is today being associated with a risk of pneumothorax and hemorrhage. Further, there are no data...
5.
Nevoral J, Drutovic D, Vaskovicova M, Benc M, Liska F, Valentova I, et al.
Sci Rep
. 2024 Sep;
14(1):21598.
PMID: 39285243
Dynamic changes in maternal‒zygotic transition (MZT) require complex regulation of zygote formation, maternal transcript decay, embryonic genome activation (EGA), and cell cycle progression. Although these changes are well described, some...
6.
Ali E, cervenkova L, Palek R, Ambrozkiewicz F, Pavlov S, Ye W, et al.
J Vis Exp
. 2024 Apr;
(206).
PMID: 38682951
The insights provided by in-situ detection of immune cells within hepatocellular carcinoma (HCC) might present information on patient outcomes. Studies investigating the expression and localization of immune cells within tumor...
7.
Prochazkova K, Vojtisek R, Vodicka J, Horova J, Hosek P, Skala M, et al.
Rep Pract Oncol Radiother
. 2024 Mar;
28(6):746-755.
PMID: 38515821
Background/objective: Hormone receptor (HR) status is one of the key factors in determining the treatment of breast cancer. Previous studies suggested that HR status may change in metastatic tissue. However,...
8.
Ali E, cervenkova L, Palek R, Ambrozkiewicz F, Hosek P, Daum O, et al.
BMC Cancer
. 2024 Jan;
24(1):142.
PMID: 38287290
Background: The prognostic significance of mast cells and different phenotypes of macrophages in the microenvironment of hepatocellular carcinoma (HCC) following resection is unclear. We aimed in this study to assess...
9.
Fiala O, Hosek P, Korunkova H, Hora M, Kolar J, Sorejs O, et al.
Cancer Med
. 2024 Jan;
13(1):e6853.
PMID: 38164124
Background: The introduction of novel hormonal therapies represented by enzalutamide (ENZ) and abiraterone acetate (ABI) has reached a great progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The...
10.
Blazek J, Hosek P, Hrabcova K, Bratova M, Kultan J, Hrnciarik M, et al.
In Vivo
. 2023 Aug;
37(5):2229-2236.
PMID: 37652490
Background/aim: The aim of this study was to investigate possible association between adverse events of nivolumab therapy and the effectiveness of treatment in patients with non-small cell lung cancer (NSCLC)....